Publications by authors named "Robert Hayashi"
Pediatric retinoblastoma survivors exhibit visual deficits. How these visual deficits impact reading skills is unknown. The purpose of this study is to assess reading level, reading acuity, and reading speed among retinoblastoma survivors.
View Article and Find Full Text PDFArticle Synopsis
- * A retrospective study analyzed data from 5,790 young patients who underwent HCT to evaluate the incidence of late effects and their associated risk factors, focusing on various health complications like avascular necrosis and diabetes.
- * The study included patients from diverse backgrounds, revealing that 60.5% were male and most were white, with major findings regarding the timing and prevalence of complications occurring within five to seven years post-transplant.
Article Synopsis
- * Strong recommendations include reducing immunosuppression as an initial management step and using the anti-CD20 monoclonal antibody (rituximab), as well as chemotherapy in specific cases.
- * There is a lack of large randomized phase III trials for treating PTLD in pediatrics, leading to reliance on clinical experience, and the report emphasizes the need for future research on this topic.
Background: Childhood cancer survivors (CCS) with chemotherapy induced sensorineural hearing loss (SNHL) are at risk for neurocognitive impairments. The purpose of this study was to determine the relationship between SNHL and cognitive function among CCS.
Procedure: Inclusion: non-CNS solid tumor diagnosis; history of platinum chemotherapy (cisplatin and/or carboplatin); 8-17 years of age; off anti-cancer treatment for ≥6 months; and English speaking.
Adaptation of Family-Based Healthy Weight Program for Children who Survived Leukemia.
Clin Pract Pediatr Psychol
March 2024
Article Synopsis
- * Focus groups with 9 survivors and 11 parents revealed concerns about mental and physical health, perceptions of weight, and barriers to healthy behaviors, leading to specific adaptations in family-based treatment (FBT).
- * The adaptations include virtual delivery methods, a focus on weight management for survivors, education on late effects, and tailored content addressing emotional health and body esteem, with a pilot trial currently evaluating the effectiveness of these changes.
Background: Childhood cancer survivors (CCS) exposed to platinum chemotherapy are at an increased risk of developing hearing loss and reporting decreased quality of life (QOL). This study compared two QOL measures; one developed for children with hearing loss, The Hearing Environments and Refection on Quality of Life (HEAR-QL), and one validated in CCS, the Patient-Reported Outcomes Measurement Information System (PROMIS), to assess their ability to evaluate QOL deficits in this population.
Methods: Subject eligibility were restricted to CCS exposed to platinum-based chemotherapy but who were free of known risk factors for cognitive impairment, (non-central nervous system tumor, no cranial radiation, or intrathecal chemotherapy).
Article Synopsis
- Defining prognostic factors for T-lymphoblastic lymphoma (T-LL) is complex, as shown in the AALL1231 trial that included children and young adults with T acute lymphoblastic leukemia or T-LL, comparing standard therapy with the addition of bortezomib.
- In the trial, 41% of patients provided bone marrow samples to measure minimal residual disease (MRD) after treatment, revealing that those with MRD levels below 0.1% had a significantly better event-free survival rate (89%) compared to those with MRD at or above 0.1% (64%).
- Cox regression analysis indicated that having MRD levels at or above 0.1%
Background: Prevalence and risk of poor psychological outcomes following rhabdomyosarcoma (RMS) are not well-established.
Methods: Participants in this cross-sectional, case-control study (n = 713 survivors, 42.5% female; mean [SD] age, 30.
Article Synopsis
- The study investigates the effects of reduced-intensity conditioning (RIC) regimens on fertility and gonadal function in adolescent and young adult survivors of hematopoietic stem cell transplantation (HCT).
- Researchers analyzed data from 326 patients aged 10 to 40 who underwent their first allogeneic HCT, focusing on hormonal levels as indicators of fertility potential and gonadal failure.
- Findings revealed that a significant majority of female HCT recipients had very low levels of AMH, indicating poor fertility potential, and that RIC might have a lower incidence of detectable AMH compared to myeloablative conditioning (MAC), although impairment was still common.
Article Synopsis
- The study focuses on treating posttransplant lymphoproliferative disease (PTLD) in pediatric solid organ transplant recipients using rituximab and third-party T cells, aiming to combat Epstein-Barr virus-infected B cell proliferation due to weakened immune systems.
- Thirteen out of 15 patients received T cell therapy within 14 days, showing it was generally well tolerated, although there were some adverse effects like organ rejection and cytokine release syndrome.
- The results indicated a 70% overall response rate for newly diagnosed patients after the first treatment cycle, with a combined two-year survival rate of 70.7%, establishing the feasibility and potential benefits of this T cell therapy approach without chemotherapy.
Article Synopsis
- Allogeneic hematopoietic cell transplantation (HCT) in pediatric patients can lead to serious complications, requiring intensive care for a notable percentage of patients post-transplant.
- A study analyzing data from multiple centers found that about 15.3% of patients needed ICU care within 5 years, with factors like patient demographics and pre-existing conditions influencing this need.
- Although survival to discharge from the ICU is high (85.7%), many patients face ongoing health issues, resulting in a significant drop in long-term survival rates, especially among those with malignancies and poor organ function.
Article Synopsis
- The article DOI: 10.3389/fonc.2023.1280587 has been corrected to address specific inaccuracies or issues.
- The corrections aim to clarify findings or improve the overall quality of the research presented.
- Readers are encouraged to refer to the updated version for accurate information and conclusions.
Article Synopsis
- Treatment options for post-transplant lymphoproliferative disease (PTLD) vary, with concerns over chemotherapy side effects influencing decisions, and this study aimed to identify late effects in survivors.
- Among 44 pediatric patients studied, 55% received chemotherapy, and while it didn't show a significant impact on survival, all patients reported experiencing late effects.
- Those treated with chemotherapy had higher rates of blood and cardiac toxicities, but fewer infections, highlighting the need for further research on late effects to optimize treatment for PTLD in children.*
Article Synopsis
- The study aimed to find risk factors that affect how quickly children and young adults clear methotrexate after treatment for leukemia or osteosarcoma.
- Researchers reviewed patient records from 2010 to 2017, focusing on factors like IV medications and urine output related to methotrexate clearance.
- Results indicated that factors such as age, type of cancer (leukemia), and certain medications were linked to delayed methotrexate clearance and longer hospital stays, suggesting opportunities for improved treatment strategies.
Article Synopsis
- The study examines the impact of treatment changes for childhood acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) on physical performance and participation restrictions in survivors compared to their siblings.
- Researchers analyzed data from 6,511 survivors and 4,127 siblings, finding that survivors had significantly higher rates of performance limitations and personal care restrictions.
- Despite advancements in treatment over the decades, the prevalence of reduced physical function did not significantly decrease, highlighting the need for ongoing screening and early interventions for cancer survivors.
PET scans for non-Hodgkin lymphoma: Answering the critical questions to assess utility.
Pediatr Blood Cancer
November 2023
Article Synopsis
- The project aimed to improve support for childhood cancer survivors experiencing neurocognitive late effects by engaging parents, healthcare providers, and educators to identify research priorities regarding communication about these impacts.
- Using a combination of the SEED method and e-Delphi consensus approach, stakeholders participated in various engagement activities, resulting in the generation of 8 key research questions over the course of a year.
- The findings highlight the effectiveness of this collaborative process, offering a framework that can be applied to other healthcare challenges while addressing gaps in care for children facing neurocognitive issues.
Article Synopsis
- Allogeneic hematopoietic cell transplantation (HCT) can lead to complications requiring intensive care, but the risk factors for these complications are not well understood due to differences among treatment centers.
- The study analyzed data from 6,995 pediatric HCT patients and found that 1,067 of them needed intensive care, with higher admission rates linked to factors like younger age, lower income, and certain pre-existing health conditions.
- Among those who were admitted to intensive care, the survival rate to discharge was 85.7%, but many experienced readmissions, and overall long-term survival rates were significantly worse for patients with certain risk factors, particularly those with malignant diseases or existing organ dysfunction.*
This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on considerations for the comprehensive care of AYA patients with cancer. Compared with older adults with cancer, AYA patients have unique needs regarding treatment, fertility counseling, psychosocial and behavioral issues, and supportive care services. The complete version of the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology addresses additional aspects of caring for AYA patients, including risk factors, screening, diagnosis, and survivorship.
View Article and Find Full Text PDFChildren's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma.
Pediatr Blood Cancer
September 2023
Article Synopsis
- Challenges remain with patients who have relapsed/refractory disease and long-term health issues for NHL survivors.
- The Children’s Oncology Group NHL Committee aims to find optimal treatments for all affected children and young adults, pushing for innovative solutions such as combining rare patient populations and international collaborations for better outcomes.
Article Synopsis
- This study explored the impact of retinoblastoma and its treatments on children's vision, specifically focusing on contrast sensitivity and saccades (eye movement).
- Eleven children aged 5-17 years who completed treatment were assessed for visual acuity, saccades, and contrast sensitivity.
- Results showed that all tested participants had decreased saccade parameters and impaired contrast sensitivity, suggesting that extensive vision evaluations are essential for optimal rehabilitation of retinoblastoma survivors.
Article Synopsis
- AYA cancer survivors show improved survival rates but are at higher risk for cardiovascular disease (CVD), particularly from therapies like anthracyclines and VEGF inhibitors.
- A study reviewing 1,165 AYA survivors found that 32% treated with anthracyclines, 22% with VEGF inhibitors, and 34% with both experienced cardiovascular toxicities, with hypertension being the most frequent issue.
- Results indicated that males are at a higher risk for toxicity from anthracycline therapy, and the combination of anthracyclines and VEGF inhibitors resulted in a 50% incidence of cardiovascular toxicities over ten years.
The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III - Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring.
Jutta Preiksaitis Upton Allen Catherine M Bollard Vikas R Dharnidharka Daniel E Dulek Robert J Hayashi
Pediatr Transplant
February 2024
Article Synopsis
- The International Pediatric Transplant Association held a conference to create guidelines for managing post-transplant lymphoproliferative disorders (PTLD) in children, focusing on how to use biomarkers like Epstein-Barr virus (EBV) levels for patient care.
- The group recommends using "EBV DNAemia" for measuring EBV DNA in blood and advises caution when comparing results from different labs. They concluded both whole blood and plasma can be used for testing, depending on the clinical situation.
- It is suggested that quantitative EBV DNAemia testing can help identify children at risk for PTLD, especially those who were EBV negative before their transplant, but overall routine surveillance is not recommended for